Fiche publication
Date publication
février 2021
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FAIVRE Jean-Christophe
Tous les auteurs :
Thureau S, Marchesi V, Vieillard MH, Perrier L, Lisbona A, Leheurteur M, Tredaniel J, Culine S, Dubray B, Bonnet N, Asselain B, Salleron J, Faivre JC
Lien Pubmed
Résumé
Stereotactic Body Radiation Therapy (SBRT) is an innovative modality based on high precision planning and delivery. Cancer with bone metastases and oligometastases are associated with an intermediate or good prognosis. We assume that prolonged survival rates would be achieved if both the primary tumor and metastases are controlled by local treatment. Our purpose is to demonstrate, via a multicenter randomized phase III trial, that local treatment of metastatic sites with curative intent with SBRT associated of systemic standard of care treatment would improve the progression-free survival in patients with solid tumor (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases compared to patients who received systemic standard of care treatment alone.
Mots clés
Bone metastases, Breast neoplasms, Lung neoplasms, MeSH: Oligometastases, Neoplasm metastasis, Prostatic neoplasms, Radiosurgery, Stereotactic radiotherapy
Référence
BMC Cancer. 2021 Feb 4;21(1):117
